Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma
L. Heinst, K. S. Lee, R. Berthold, I. Isfort, S. Wosnig, A. Kuntze, S. Hafner, B. Altvater, C. Roessig, P. Aman, E. Wardelmann, C. Scholl, W. Hartmann, S. Froehling, M. Trautmann
This study identifies WEE1 kinase activity as a therapeutic target in FUS::DDIT3-driven myxoid liposarcoma by showing its role in replication stress tolerance and cell survival.
Clinical Cancer Research · Aug 29, 2024Peer-reviewedCancer Biology